Last reviewed · How we verify
NCT03099876
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
trial testing treatment period in Helicobacter Pylori Infection in 320 participants. Status unknown.
1 December 2017
Quick facts
| Lead sponsor | Il-Yang Pharm. Co., Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 320 |
| Start date | 1 March 2017 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 December 2018 |
| Sites | 4 locations across South Korea |
Drugs / interventions tested
- treatment period
Conditions studied
- Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →
Sponsor
Il-Yang Pharm. Co., Ltd. — full company profile →
Who can join
Adults 20 to 80, any sex, with Helicobacter Pylori Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori.
Lee SW, Moon SJ, Kim SH, Jung SH, et al · · 2020 · cited 4× · PMID 32957336 · DOI 10.1097/md.0000000000022137
Verify or expand the search:
- PubMed search for NCT03099876
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Helicobacter Pylori Infection
Currently open trials in the same condition.
- NCT07285096 — P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication · recruiting
- NCT07358130 — Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy · NA · recruiting
- NCT07165444 — Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatme · NA · recruiting
- NCT06929962 — VA Dual Sequential Therapy · Phase 4 · recruiting
- NCT06959368 — Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication · Phase 4 · recruiting
Other Il-Yang Pharm. Co., Ltd. trials
Trials by the same sponsor.
- NCT07322991 — Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects. · Phase 1 · completed
- NCT05617651 — Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T · Phase 1 · unknown
- NCT06665412 — Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML · recruiting
- NCT04381689 — Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants · Phase 3 · active not recruiting
- NCT06284876 — Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03099876 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Il-Yang Pharm. Co., Ltd.
- Last refreshed: 7 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03099876.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing